𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II evaluation of galactitol in head and neck cancer: A southwest oncology group study

✍ Scribed by Haas, Charles D. ;Lehane, Daniel ;Bottomley, Richard

Publisher
John Wiley and Sons
Year
1983
Tongue
English
Weight
208 KB
Volume
11
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

A phase II evaluation of DAG in head and neck cancer patients produced one partial response and one patient with prolonged stable disease from nine fully evaluable patients with squamous carcinomas. One partial response was produced in a patient with anaplastic thyroid carcinoma. No drug deaths or life‐threatening toxicity were reported. Further evaluation of DAG in thyroid tumors is warranted.

📜 SIMILAR VOLUMES

Phase II evaluation of bleomycin. A Sout
Phase II evaluation of bleomycin. A Southwest Oncology Group study
✍ Charles D. Haas; Charles A. Coltman Jr.; Jeffrey A. Gottlieb; Arthur Haut; James 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB 👁 2 views

Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/mz was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and

Phase I evaluation of vindesine in child
Phase I evaluation of vindesine in children: A southwest oncology group pilot study
✍ Komp, Diane ;Vats, Tribhawan ;Shepherd, Dell A. ;Vietti, Teresa ;Hoogstraten, Ba 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 374 KB

## Abstract Twenty‐one children (19 with leukemia) were given 34 courses of vindesine on a weekly or twice‐weekly schedule in escalating doses. Thirty‐three courses were fully or partially evaluable for response and/or toxicity. Granulocyto‐penia was the dose‐limiting toxicity. Transient jaw, neck,

Adjuvant therapy of osteosarcoma—A Phase
Adjuvant therapy of osteosarcoma—A Phase II trial : Southwest Oncology Group study 9139
✍ Mark M. Zalupski; Cathryn Rankin; James R. Ryan; David R. Lucas; Jeffrey Muler; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract ## BACKGROUND The objective of this study was to estimate the time to treatment failure and survival rate of the three‐drug combination of doxorubicin, cisplatin, and ifosfamide as primary and postoperative, adjunctive treatment for teenagers and adults with osteosarcoma (OS). ## METH